

ID Seminar:

A brave new world: new options for the treatment of Rifampicin Resistant TB



THURSDAY

April 13, 2023
8am EST

SPEAKER

DR. FRANCESCA CONRADIE

Co-Chair
National Clinical Advisory Committee (NCAC)
South Africa

Dr. Conradie's research career began with investigation into HIV treatment and moved, in 2009, to treatment for Rifampicin Resistant (RR) -TB. She was the Principal Investigator for the TB Alliance's NIX trial that led to the registration by the FDA of BPaL for XDR TB, and is also the holder of USAID Grant BEAT Tuberculosis: an investigation into a short all-oral regimen for RR TB. Dr. Conradie has been the co-chair of the National Clinical Advisory Committee (NCAC) since 2012. This body was formed originally to provide clinical governance to Bedaquiline Clinical Access Programs (CAP) site clinicians in South Africa, which allows access to new drugs and regimens prior to their registration and incorporation into national policy within the South African National TB Program (NTP). The committee also provides expert clinical advice to the National Drug-Resistant TB directorate, gives input into the National RR-TB guidelines and advises on the addition of new drugs into those treatment guidelines.

Zoom ID: 973 9383 2588 Passcode: 222



Tuberculosis Research Advancement Center
Emory/Georgia



EMORY | SCHOOL OF MEDICINE